The aim of this cross-sectional survey was to compare the health-economic consequences for allergic rhinitis (AR) patients treated with sublingual Immunotherapy (SLIT) in terms of direct and indirect costs with a reference population of patients receiving standard of care pharmacological therapy. Primary objective was to analyse the health-economic consequences of SLIT for grass pollen allergy in Sweden vs reference group waiting for subcutaneous immunotherapy (SCIT). A questionnaire was mailed to two groups of AR patients. The questionnaire was distributed to 548 patients, 307 with SLIT and 241 in reference group (waiting for SCIT). Response rate was 53.8%. Mean annual costs were higher for reference patients than SLIT group; € 3907 (SD 4268) vs € 2084 (SD 1623) p < 0.001. Mean annual direct cost was higher for SLIT-patients, € 1191 (SD 465) than for reference, € 751 (SD 589) p < 0.001. Mean annual indirect costs for combined absenteeism and presenteeism were lower for patients treated with SLIT, € 912 (SD 1530), than for reference, € 3346 (SD 4120) p < 0.001, with presenteeism as main driver. SLIT seems to be a cost-beneficial way to treat seasonal AR. This information might be used to guide future recommendations.

中文翻译：

---

HealthSWEDE：舌下免疫治疗的成本——瑞典问卷调查

这项横断面调查的目的是比较接受舌下免疫疗法 (SLIT) 治疗的过敏性鼻炎 (AR) 患者在直接和间接成本方面与接受标准护理药物治疗的患者参考人群的健康经济后果。主要目的是在瑞典与等待皮下免疫治疗 (SCIT) 的参考组中分析 SLIT 对草花粉过敏的健康经济后果。一份问卷被邮寄给两组 AR 患者。问卷分发给 548 名患者，其中 307 名患有 SLIT，241 名参考组（等待 SCIT）。响应率为 53.8%。参考患者的平均年费用高于 SLIT 组；€ 3907 (SD 4268) vs € 2084 (SD 1623) p < 0.001。SLIT 患者的平均年直接成本较高，€ 1191 (SD 465) 比作为参考，€ 751 (SD 589) p < 0.001。使用 SLIT 治疗的患者的缺勤和出勤综合年平均间接成本为 912 欧元 (SD 1530)，低于参考值 3346 (SD 4120) p < 0.001，出勤率是主要驱动因素。SLIT 似乎是治疗季节性 AR 的一种成本效益高的方法。此信息可用于指导未来的建议。